Bavarian begins phase III trial of RSV vaccine in older adults

The first person has received Bavarian Nordic’s vaccine candidate against respiratory syncytial virus in a late-stage global study.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic has administered the first shot of its RSV vaccine in a phase III trial with older adults, and the global study is therefore now underway, the company has announced in a press release.

The trial will assess the efficacy of Bavarian’s candidate, MVA-BN RSV, in older patients with lower-respiratory tract disease caused by respiratory syncytial virus (RSV).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs